Alivus Life Sciences Limited has announced the approval of a share purchase agreement to acquire a 76% stake in IQGEN-X Pharma Private Limited. The aggregate consideration for this acquisition is approximately INR 9.12 crores, subject to adjustments. This strategic move is expected to expand Alivus Life Sciences’ offerings and enhance its market presence in the pharmaceutical sector by providing a wider spectrum of solutions.
Strategic Acquisition Approved
Alivus Life Sciences Limited has taken a significant step towards expanding its operations and market reach with the board’s approval to acquire a 76% stake in IQGEN-X Pharma Private Limited. The decision was made during a board meeting held on August 18, 2026. This acquisition signifies a strategic expansion for Alivus Life Sciences within the pharmaceutical industry.
Deal Details and Consideration
The aggregate consideration for the acquisition of IQGEN-X Pharma Private Limited is set at approximately INR 9.12 crores. This amount is subject to customary adjustments as outlined in the Share Purchase Agreement (SPA). The transaction involves the acquisition of 8,60,589 equity shares, each with a face value of INR 10, representing 76% of the paid-up equity share capital of IQGEN-X Pharma Private Limited.
About IQGEN-X Pharma Private Limited
IQGEN-X Pharma Private Limited, incorporated under the Companies Act, 2013, in October 2016, is engaged in the formulation development of Oral Solids, Sterile Injectables, and Ophthalmic solutions. The company focuses on regulated and semi-regulated markets. Its turnover for the last three financial years has shown growth: INR 267.5 Lacs in 2023-24, INR 318.2 Lacs in 2024-25, and projected INR 348.0 Lacs for 2025-26. The company operates from India.
Rationale and Impact of Acquisition
The acquisition is poised to provide Alivus Life Sciences Limited with a wider spectrum of offerings, enabling it to deliver a complete end-to-end solution to its customers in both the Active Pharmaceutical Ingredient (API) and Contract Development and Manufacturing Organization (CDMO) spaces. The transaction does not involve related party dealings, and no promoter has any interest in the entity being acquired, ensuring it is conducted at arm’s length.
Indicative Timeline
The indicative time period for the completion of this acquisition is anticipated to be around December 6, 2026, or another date as mutually agreed upon by the parties executing the Share Purchase Agreement. This completion is contingent upon the fulfilment of certain Conditions Precedent stipulated in the SPA. If these conditions are not met within the specified timelines, the sellers may enter into a Business Transfer Agreement to acquire the entire business, including employees and assets, from IQGEN-X Pharma Private Limited.
Source: BSE
